Dry eye diagnostic nears US approval

Article

The TearLab Osmolarity System and Osmolarity Test Card have been submitted to the FDA for premarket authorization in the US, according to an announcement from the manufacturer of TearLab, Occulogix.

The TearLab Osmolarity System and Osmolarity Test Card have been submitted to the FDA for premarket authorization in the US, according to an announcement made by TearLab's manufacturer, Occulogix.

To support the application, OcuSense, a subsidiary of Occulogix, has conducted a multicentre safety and efficacy study of the System, which requires <50 nanolitres of tears to measure osmolarity. OcuSense will announce its results at this year's meeting of the American Academy of Ophthalmology.

The TearLab System, which is CE marked, is currently available in selected European countries.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
Related Content
An older woman with glasses on sits and reads a book, a mug of coffee in front of her. Concept image for geographic atrophy lesions (GA) and age-related macular degeneration (AMD). Image credit: ©MiguelAngel – stock.adobe.com

Progression rates vary in subtypes of geographic atrophy lesions

Lynda Charters
August 28th 2025
Article
Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
August 28th 2025
Podcast
The Eiffel Tower/La Tour Eiffel, as viewed from under a bridge in Paris, France. Concept image for EURETINA 25th anniversary and retina specialist meeting conference in Europe. Image credit: ©Dario – stock.adobe.com

What to expect at this year's European Society of Retina Specialists (EURETINA) Congress

Hattie Hayes
August 28th 2025
Article
Concept image for the balancing of energy efficiency and time in refractive surgery phacoemulsification. A scale, with a laser beam of blue light on one side, and an analog alarm clock on the other side. The laser beam of blue light is surrounded by static. Created with Canva Magic AI.

Keys to optimising phaco efficiency

Marta Ibarz, MD, PhD
August 28th 2025
Article
European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

Hattie Hayes
August 28th 2025
Article
A family, two parents or grandparents and a child, walk outside in a park. Concept image for urban exposure to green space, dry eye disease, dry eye prevention, tear meniscus and ocular health. Image credit: ©Victoriia – stock.adobe.com

Green spaces may have "protective effect" against dry eye disease

Lynda Charters
August 28th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.